Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
BIPHETAMINE 20 is an oral extended-release capsule containing an amphetamine combination, approved in 1955 as a small-molecule NDA. The drug's specific mechanism of action and labeled indications are not provided in available data, though the formulation suggests CNS stimulant activity. This is a legacy product with a 68-year market history.
As LOE approaches with moderate competitive pressure (30/100), brand teams face declining revenue trajectory and will likely shift focus to niche positioning or portfolio wind-down activities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on BIPHETAMINE 20 offers limited career growth opportunity given the product's LOE-approaching lifecycle and zero linked job openings. Professionals on this brand would focus on defensive commercial strategies, managed care negotiations, and market share protection rather than expansion or innovation initiatives.
Worked on BIPHETAMINE 20 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.